7 results about "Epidermal keratinocyte" patented technology

[Summary] [Problems] The main purpose of this invention is to provide a technique for inducing an epidermal keratinocyte that can produce a three-dimensional cultured skin model with a multi-layered horny cell layer, from a pluripotent stem cell. [Solution] The present invention is a method for inducing differentiation from a pluripotent stem cell to an epidermal keratinocyte, using a non-detached cell after being treated with a cell detaching agent in the inducing step from the pluripotent stem cell, wherein when applying the epidermal keratinocyte to a three-dimensional cultured skin model, a three-dimensional cultured skin model in which the horny cell layer is multi-layered is obtained.

The present invention relates to a cosmetic skincare composition, preferably anti-aging, for improving the superficial visual appearance of the skin, giving it a more youthful appearance, comprising an extract of Primrose and an extract of dedifferentiated cells of Pale Iris. The invention also relates to the use of such a combination to inhibit the expression of MMP-2 and MMP-9 in epidermal keratinocytes.

The invention provides an HPV (human papillomavirus) infected human epidermal keratinocyte model and a construction method and application thereof, and relates to the technical field of molecular biology, an HPV genome is integrated to a KRT5 site of genome DNA (deoxyribonucleic acid) of human epidermal keratinocytes to obtain the HPV infected human keratinocyte model, stable integration and expression of an HPV whole genome are successfully realized, and the HPV infected human keratinocyte model is obtained. The position effect caused by random insertion is avoided, and the genetic stability is ensured; the model has the synergistic expression function of HPV early and late genes, maintains the time sequence of virus gene expression, realizes HPV virus particle assembly, and simulates the complete life cycle of HPV. The technical problem that in the prior art, an infection model cannot simulate the complete life cycle of the HPV is solved.

The present invention addresses the problem of providing a novel therapeutic agent that is effective against diseases involving stratified squamous epithelial cells such as dry eye syndrome. The present invention is an agent for promoting normal differentiation / maturation of stratified squamous epithelial cells, which comprises a secretion of mesenchymal stem cells. It is preferable that the secretions not include animal serum, that the mesenchymal stem cells be adipose-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and that the stratified squamous epithelial cells be at least one selected from the group consisting of corneal epithelial cells, conjunctival epithelial cells, epidermal keratinocytes, oral epithelial cells, epiglottic epithelial cells, esophageal epithelial cells, vaginal epithelial cells, vocal fold epithelial cells, nasal epithelial cells, and nasal vestibular epithelial cells.

The present invention relates to: a composition for regenerating or repairing skin damage and / or promoting epidermal cell differentiation, comprising calcium lactate as an active ingredient; and a method therefor, wherein the skin damage includes that caused by ultraviolet rays. The present invention induces differentiation of epidermal keratinocytes so as to form a biological barrier and allows the skin to maintain moisture on its own, and, as a temporary effect, plays a role in protecting the skin from UV by forming nanoparticles on the surface thereof.

The invention belongs to the field of drugs for inflammatory dermatosis, and discloses an application of myrcene in preparation of drugs for inflammatory dermatosis, which comprises the following steps: combining a mouse AD model (DNCB) with human epidermal keratinocytes (NHEK) and mouse macrophages (RAW264.7); the improvement effect of the MYR is evaluated by adopting histology and immunofluorescence technologies; by integrating transcriptomics and proteomics analysis, the molecular mechanism of MYR for relieving AD symptoms is clarified, and the causal relationship is verified by using a pharmacological inhibitor. The conclusion of the invention is as follows: Myrcene alleviates AD sample inflammation by inhibiting FAK / Src-YAP / TAZ axis. A repeatable mechanism framework is established by the data, and the natural monoterpenoids are associated with biomechanical-nuclear signal transduction and innate immune regulation in AD.

Traditional research focusing on protein synthesis has focused on the total amount of protein, and therefore requires components that either suppress the decrease in the amount of newly synthesized protein or promote its synthesis. [Solution] Focusing on the synthesis of new proteins, and utilizing a method for evaluating the amount of new protein synthesis in dermal fibroblasts and epidermal keratinocytes, neem leaf extract and kudzu extract are provided as inhibitors of the decrease in the amount of new protein synthesis or as promoters of new protein synthesis.